AgencySpy LostRemote TVNewser TVSpy FishbowlNY FishbowlDC GalleyCat SocialTimes

Posts Tagged ‘Botox’

Your New Hangover Remedy Is In The Children’s Medicine Section

Lamenting the fact that his hangovers were getting worse as he got older, one Slate writer ran to the local drugstore on the advice of musician Jason Isbell. Pedialyte, Isbell told The New York Times Magazine, will get you back to form. “It’s like 10 Gatorades in one bottle.” When he got to the store, he was even more excited to find that Pedialyte comes in freezer pop form.

The next morning, after a night at the bar, Nell McShane Wulfhart needed one of those Pedialyte pops. “Cold, sweet, and refreshing, the pops were the most pleasant way I’d ever found to get fluids back into my body,” he says.

All of that is great, but Pedialyte is really meant to help sick children with the occasional tummy ache, not a lush adult who has bellied up to the bar a couple times too many. So is this the kind of off-label use that works in Pedialyte’s favor?

Read more

Mediabistro Course

Mediabistro Job Fair

Mediabistro Job FairLand your next big gig! Join us on January 27 at the Altman Building in New York City for an incredible opportunity to meet with hiring managers from the top New York media companies, network with other professionals and industry leaders, and land your next job. Register now!

‘CR Magazine’ Names Best Corporate Citizens

A Johnson Controls engineer examining a battery that will power a hybrid electric vehicle. Photo: Dan Irving, Johnson Controls

Topping Corporate Responsibility Magazine‘s 12th annual “100 Best Corporate Citizens List” (released today) is Johnson Controls, the industry and technology company based in Wisconsin. The company went from number 22 in 2009 to the top of the list for 2010.

CR determines its best corporate citizens based on their activity in seven areas: the environment, climate change, employee relations, human rights, finance, philanthropy, and government. Overall, companies scored better this year over last.

Rounding out the top five are Campbell Soup, International Business Machines (IBM), Bristol-Myers Squibb, and Mattel. CR also notes those who are under investigation or have a judgment against them from a legal or regulatory body, which excludes that company from the list for the following three years.

Read more

GCI Health To Promote Botox for Migraines

Allergan has selected GCI Health to support the launch of Botox for use in the preventive treatment of chronic migraine in adults.

Botox was approved by the FDA on October 15 for use in preventing migraines in patients who suffer from headaches that last four or more hours during 15 or more days in a month. According to the press release announcing the relationship, this is the “sixth therapeutic indication for the product” since 1989.

“Botox, with current annual sales of $1.4 billion, could eventually capture $600 million or more in additional annual sales from the migraine indication, according to analysts,” Reuters reports.

While the financial results have made it a favorite on Wall Street, the story continues, Allergan agreed to plead guilty last month and pay $600 million to resolve federal accusations about Botox marketing practices.

“The Justice Department accused Allergan of paying kickbacks to doctors to prescribe Botox for unapproved uses — such as treating headaches, pain and juvenile cerebral palsy — and teaching doctors how to bill for such ‘off-label’ uses,” the Reuters story said.

Botox Maker Settles Charges for $600 Million

botox.jpg Allergan, the makers of Botox, have agreed to pay a $600 million settlement for charges that the company promoted the off-label use of the drug. According to the complaint, Allergan had a marketing program in place that would include “kickbacks” to doctors for prescribing Botox for things that it hasn’t been approved for, like pain treatment. The FDA is considering approval for Botox’s use in treating chronic migraines.

Allergan spokeswoman Caroline Van Hove denied kickback and fraud allegations in an emailed statement to the New York Times. The company issued a statement yesterday, saying that it plead guilty to one misdemeanor “misbranding” charge and agreed to pay $225 million to resolve civil claims.

“This is part of a departmentwide and administrationwide effort to really crack down on health care fraud,” Tony West, assistant attorney general for the civil division of the Justice Department, told the New York Times.

[Image via BioJobBlog]